Science News
from research organizations

New antibody therapy dramatically improves psoriasis symptoms in clinical trial

Date:
March 13, 2015
Source:
Rockefeller University
Summary:
Many patients suffering from psoriasis showed significant recovery after just a single dose of an experimental treatment with a human antibody that blocks an immune signaling protein crucial to the disease, researchers report. By the end of the trial nearly all of the 31 patients to receive treatment saw dramatic, if not complete, improvement in their symptoms.
Share:
FULL STORY

A sample from one psoriasis patient shows thickening of the outer layer of skin, known as the epidermis (top). Eight weeks after treatment, the epidermis has thinned to a normal level (bottom).
Credit: Laboratory of Investigative Dermatology at Rockefeller University/Journal of Allergy and Clinical Immunology

Many patients suffering from psoriasis showed significant recovery after just a single dose of an experimental treatment with a human antibody that blocks an immune signaling protein crucial to the disease, researchers report. By the end of the trial, conducted at Rockefeller University and seven other centers, nearly all of the 31 patients to receive treatment saw dramatic, if not complete, improvement in their symptoms

"The striking result we achieved using a human antibody that targets the signal interleukin-23 suggests we are on the threshold of doing something very different from our current model of treating psoriasis with immunosuppressive drugs throughout an adult lifetime," says study author James Krueger, director of the Milstein Medical Research Program, D. Martin Carter Professor in Clinical Investigation and head of the Laboratory of Investigative Dermatology. "It raises the possibility of working toward long-term remission -- in other words, a cure." The Journal of Allergy and Clinical Immunology published the results on March 12.

Psoriasis is a debilitating disease in which the body's immune system mistakenly turns on the skin, producing red, itchy, scaly patches. In 2004, Krueger and colleagues suggested a dominant role for interleukin-23 in the disease, and research since then has supported this hypothesis. It appears that interleukin-23, a type of immune signaling molecule known as a cytokine, kicks off a cascade of interactions that leads to inflammation in the skin and excessive growth of skin cells and dilation of blood vessels.

The discovery of interleukin-23's role has led to tests of a number of new antibody-based therapies that target it, but the compound, known as BI 655066, stands out. BI 655066 is a human antibody that targets interleukin-23 and blocks it from binding to the receptors on cells that respond to it. Only a single treatment produced what the team describes as "rapid, substantial, and durable clinical improvement in patients with moderate-to-severe psoriasis." On average, patients who received the treatment had a more than 80 percent improvement in the severity and extent of their skin lesions that continued until tracking ended six weeks after treatment. Meanwhile, genetic sequencing from skin samples revealed that the antibody's action reduced the expression of many of the cytokines and other molecules that define psoriasis.


Story Source:

Materials provided by Rockefeller University. Note: Content may be edited for style and length.


Journal Reference:

  1. James G. Krueger, Laura K. Ferris, Alan Menter, Frank Wagner, Alexander White, Sudha Visvanathan, Bojan Lalovic, Stella Aslanyan, Elaine E.L. Wang, David Hall, Alan Solinger, Steven Padula, Paul Scholl. Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2015; DOI: 10.1016/j.jaci.2015.01.018

Cite This Page:

Rockefeller University. "New antibody therapy dramatically improves psoriasis symptoms in clinical trial." ScienceDaily. ScienceDaily, 13 March 2015. <www.sciencedaily.com/releases/2015/03/150313171614.htm>.
Rockefeller University. (2015, March 13). New antibody therapy dramatically improves psoriasis symptoms in clinical trial. ScienceDaily. Retrieved May 29, 2017 from www.sciencedaily.com/releases/2015/03/150313171614.htm
Rockefeller University. "New antibody therapy dramatically improves psoriasis symptoms in clinical trial." ScienceDaily. www.sciencedaily.com/releases/2015/03/150313171614.htm (accessed May 29, 2017).

RELATED STORIES